» Articles » PMID: 29531107

Digital Rectal Examination for Prostate Cancer Screening in Primary Care: A Systematic Review and Meta-Analysis

Overview
Journal Ann Fam Med
Specialty Public Health
Date 2018 Mar 14
PMID 29531107
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Although the digital rectal examination (DRE) is commonly performed to screen for prostate cancer, there is limited data to support its use in primary care. This review and meta-analysis aims to evaluate the diagnostic accuracy of DRE in screening for prostate cancer in primary care settings.

Methods: We searched MEDLINE, Embase, DARE (Database of Abstracts of Reviews of Effects), Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and CINAHL (Cumulative Index to Nursing and Allied Health Literature) from their inception to June 2016. Six reviewers, in pairs, independently screened citations for eligibility and extracted data. Pooled estimates were calculated for sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of DRE in primary care settings using an inverse-variance meta-analysis. We used QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies 2) and GRADE (Grades of Recommendation Assessment, Development, and Evaluation) guidelines to assess study risk of bias and quality.

Results: Our search yielded 8,217 studies, of which 7 studies with 9,241 patients were included after the screening process. All patients analyzed underwent both DRE and biopsy. Pooled sensitivity of DRE performed by primary care clinicians was 0.51 (95% CI, 0.36-0.67; I = 98.4%) and pooled specificity was 0.59 (95% CI, 0.41-0.76; I = 99.4%). Pooled PPV was 0.41 (95% CI, 0.31-0.52; I = 97.2%), and pooled NPV was 0.64 (95% CI, 0.58-0.70; I = 95.0%). The quality of evidence as assessed with GRADE was very low.

Conclusion: Given the considerable lack of evidence supporting its efficacy, we recommend against routine performance of DRE to screen for prostate cancer in the primary care setting.

Citing Articles

Exosomal Liquid Biopsy in Prostate Cancer: A Systematic Review of Biomarkers for Diagnosis, Prognosis, and Treatment Response.

Hamid Y, Rabbani R, Afsara R, Nowrin S, Ghose A, Papadopoulos V Int J Mol Sci. 2025; 26(2).

PMID: 39859516 PMC: 11765602. DOI: 10.3390/ijms26020802.


The Value of Digital Rectal Examination (DRE) in Prostate Cancer Diagnostics.

Debo-Aina A, Martindale A, Amjad J, Smekal M, Nkwam N Cureus. 2025; 16(12):e75390.

PMID: 39781118 PMC: 11709418. DOI: 10.7759/cureus.75390.


Prostate Cancer Patients' Perceptions Regarding the Relevance of a Digital Rectal Examination During Their Follow-Up After Radiation Therapy.

Klein C, Bosc N, Marty S, Calen L, Debard C, Robert G Cancer Med. 2025; 14(1):e70563.

PMID: 39744784 PMC: 11693983. DOI: 10.1002/cam4.70563.


An Unlabeled Electrochemical Immunosensor Uses Poly(thionine) and Graphene Quantum Dot-Modified Activated Marigold Flower Carbon for Early Prostate Cancer Detection.

Cotchim S, Kongkaew S, Thavarungkul P, Kanatharana P, Limbut W Biosensors (Basel). 2024; 14(12).

PMID: 39727854 PMC: 11674062. DOI: 10.3390/bios14120589.


[Early detection of prostate cancer-individualized, risk-adapted and successful].

Hubner A, Busshoff I, Lakes J, Al-Monajjed R, Radtke J, Albers P Urologie. 2024; 64(1):14-23.

PMID: 39609267 DOI: 10.1007/s00120-024-02478-1.


References
1.
Nensi A, Chande N . A survey of digital rectal examination training in Canadian medical schools. Can J Gastroenterol. 2012; 26(7):441-4. PMC: 3395445. DOI: 10.1155/2012/681357. View

2.
Yilmaz O, Kurul O, Ates F, Soydan H, Aktas Z . Does an asymmetric lobe in digital rectal examination include any risk for prostate cancer? results of 1495 biopsies. Int Braz J Urol. 2016; 42(4):704-9. PMC: 5006765. DOI: 10.1590/S1677-5538.IBJU.2014.0598. View

3.
Cui T, Kovell R, Terlecki R . Is it time to abandon the digital rectal examination? Lessons from the PLCO Cancer Screening Trial and peer-reviewed literature. Curr Med Res Opin. 2016; 32(10):1663-1669. DOI: 10.1080/03007995.2016.1198312. View

4.
Allard C, Dason S, Lusis J, Kapoor A . Prostate cancer screening: Attitudes and practices of family physicians in Ontario. Can Urol Assoc J. 2012; 6(3):188-93. PMC: 3367015. DOI: 10.5489/cuaj.11290. View

5.
Crawford E, Leewansangtong S, Goktas S, Holthaus K, Baier M . Efficiency of prostate-specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age-specific reference range as a cutoff for abnormal values. Prostate. 1999; 38(4):296-302. DOI: 10.1002/(sici)1097-0045(19990301)38:4<296::aid-pros5>3.0.co;2-p. View